Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1158)	5/27/1998 3:27:00 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 2742

<<Guess anything is possible..... but..... do you really think that Galton could distinguish a university from his butt?>> Seems like a reasonable question! <g> Unfortunately, I've bet that CIST's board and BlueStone can. It's amazingly frustrating that, a year and a half after the IMNX settlement, CIST is trading at 1/3 book value. From a shareholder value perspective, clearly the quickest, most efficient way to increase share price is to merge with a company with complementary technology - e.g., an immunotherapeutics company looking for adjuvant technology - and spin off the reagents business. The recent proposed merger between T Cell Sciences and Virus Research Institute is an example of what's going on in the business world. TCEL was looking for adjuvant technology, found a company that has it, and plans to merge with it. Piece of cake. It's long past time for BlueStone, Galton, and the rest of the board to perform. I hope shareholders don't tolerate much more of this. Rudy